Efficacy of a triple therapy with rabeprazole, amoxicillin, and faropenem as second-line treatment after failure of initial Helicobacter pylori eradication therapy

Hepato-Gastroenterology

Volumn 52, Issue 62, 2005, Pages 645-648

  Togawa, Jun Ichi ^a,b   Inamori, Masahiko ^a   Fujisawa, Nobutaka ^a   Takahashi, Hirokazu ^a   Yoneda, Masato ^a   Kawamura, Harunobu ^a   Abe, Yasunobu ^a   Kirikoshi, Hiroyuki ^a   Kobayashi, Noritoshi ^a   Sakaguchi, Takashi ^a   Takamura, Tomoo ^a   Nakajima, Atsushi ^a   Ueno, Norio ^a   Sekihara, Hisahiko ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

CYP2C19; Drug metabolism; Drug resistance; Genetic polymorphism; Proton pump inhibitor

Indexed keywords

AMOXICILLIN; CARBON 13; CLARITHROMYCIN; FROPENEM; LANSOPRAZOLE; RABEPRAZOLE; UREA; UREASE;

ADULT; ADVERSE DRUG REACTION; AGED; ARTICLE; BACTERIUM CULTURE; DILUTION; DRUG EFFICACY; DRUG SENSITIVITY; ERADICATION THERAPY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HOMOZYGOSITY; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TREATMENT FAILURE; UREA BREATH TEST;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGED; AGED, 80 AND OVER; AMOXICILLIN; ANTI-BACTERIAL AGENTS; BENZIMIDAZOLES; BETA-LACTAMS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LACTAMS; MIDDLE AGED; OMEPRAZOLE; RETREATMENT; TREATMENT OUTCOME;

EID: 20144387078     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Asaka M, Satoh K, Sugano K, Sugiyama T, Takahashi S, Fukuda Y, Ota H, Murakami K, Kimura K, Shimoyama T: Guidelines in the management of Helicobacter pylori infection in Japan. Helicobacter 2001; 6:177-186.
2. Ohkusa T, Watanabe M: A strategy for second-line anti-Helicobacter pylori therapy in patients with previously failed treatment. Nippon Rinsho 2001; 59:323-327.
3. Megraud F, Doermann HP: Clinical relevance of resistant strains of Helicobacter pylori: a review of current data. Gut 1998; 43 (Suppl):S61-65.
4. Furuta T, Ohashi K, Kamata T, Takashima M, Kosuge K, Kawasaki T, Hanai H, Kubota T, Ishizaki T, Kaneko E: Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 1998; 129:1027-3100.
5. Ishizaki T, Horai Y: Review article: cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole. Aliment Pharmacol Ther 1999; 13:27-36.
6. Shirai N, Furuta T, Moriyama Y, Okochi H, Kobayashi M, Xiao F, Kosuge K, Nakagawa K, Hanai H, Chiba K, Ohashi K, Ishizaki T: Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther 2001; 15:1929-1937.
7. Hasegawa M, Saika T, Matsuzaki K, Kobayashi I, Fujioka T, Nasu M, Saionji K, Igari J: In vitro activities of faropenem against clarithromycin resistance Helicobacter pylori isolates. Kansenshogaku Zasshi 1998; 72:207-210.
8. Kobayashi I, Hasegawa M, Saika T, Nishida M, Fujioka T, Nasu M: A new semi-solid agar dilution method for determining amoxycillin, clarithromycin and azithromycin MICs for Helicobacter pylori isolates. J Antimicrob Chemother 1997; 40:713-716.
9. Furuta T, Baba K, Takashima M, Futami H, Arai H, Kajimura M, Hanai H, Kaneko E: Effect of Helicobacter pylori infection on gastric juice pH. Scand J Gastroenterol 1998; 33:357-363.
10. Goodwin CS, Mendall MM, Northfield TC: Helicobacter pylori infection. Lancet 1997; 349:265-269.
11. Adachi K, Katsube T, Kawamura A, Takashima T, Yuki M, Amano K, Ishihara S, Fukuda R, Watanabe M, Kinishita Y: CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole. Aliment Pharmacol Ther 2000; 14:1259-1266.
12. European Helicobacter pylori Study Group: Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. Gut 1997; 41:8-13.
13. Gisbert JP, Boixeda D, Bermejo F, Nieves RM, Jesus HM, Angles AM, Garcia AI, Martin DAC, Garcia PA: Re-treatment after Helicobacter pylori eradication failure. Eur J Gastroenterol Hepatol 1999; 11:1049-1054.
14. Rinaldi V, Zullo A, De Francesco V, Hassan C, Winn S, Stoppino V, Faleo D, Attili AF: Helicobacter pylori eradication with proton pump inhibitor-based triple therapies and re-treatment with ranitidine bismuth citrate-based triple therapy. Aliment Pharmacol Ther 1999; 13:163-168.
15. Gomollon F, Ducons JA, Ferrero M, Garcia CJ, Guirao R, Simon MA, Montoro M: Quadruple therapy is effective for eradicating Helicobacter pylori after failure of triple proton-pump inhibitor-based therapy: a detailed, prospective analysis of 21 consecutive cases. Helicobacter 1999; 4:222-225.
16. Lee JM, Breslin NP, Hyde DK, Buckley MJ, O'Morain CA: Treatment option for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice. Aliment Pharmacol Ther 1999; 13:489-496.
17. Chan FK, Sung JJ, Suen R, Wu JC, Ling TK, Chung SC: Salvage therapies after failure of Helicobacter pylori eradication with ranitidine bismuth citrate-based therapies. Aliment Pharmacol Ther 2000; 14:91-95.
18. Abstracts of the 5th annual meeting of Nippon Helicobacter Gakkai 1999; pp. 59-62.
19. Pearce RE, Rodrigues AD, Goldstein JA, Parkinson A: Identification of the human P450 enzymes involved in lansoprazole metabolism. J Pharmacol Exp Ther 1996; 277:805-816.
20. Yasuda S, Horai Y, Tomono Y, Nakai H, Yamato C, Manabe K, Kobayashi K, Chiba K, Ishzaki T: Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to Symphony 4′-hydroxylation status. Clin Pharmacol Ther 1995; 58:143-154.
21. Meyer UA: Metabolic interaction of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs. Eur J Gastroenterol Hepatol 1996; (Suppl 1):S21-25.
22. De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA: Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994; 46:594-598.
23. De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA: The major genetic defect responsible for polymorphism of S-mephenytoin metabolism in human. J Biol Chem 1994; 269:15419-5422.